Copyright
©The Author(s) 2022.
World J Virol. Sep 25, 2022; 11(5): 375-390
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.375
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.375
Study | Type of study | Location | Number of participants | Recommendation |
Diagnostic and prognostic utility of natriuretic peptides | ||||
Arcari et al[20], 2020 | Multicenter, Observational | Italy | 111 | Positive correlation between the rise in NPs and COVID-19 disease severity. Half of these patients had their NP level above the upper limit of normal |
Caro-Codón et al[40], 2021 | Population | Spain | 396 | In patients with history of HF, elevation in NT-proBNP above the cut-off for normal suggested development of acute HF |
Gao et al[41], 2020 | Multicenter, Prospective | China | 402 | This study proposed a triple cut point strategy of NT-proBNP (HF unlikely if NT-proBNP < 300pg/L, grey zone 300-900 pg/L and HF likely if > 900 pg/L) for its role in developing acute HF and in determining prognosis. Thirty day mortality in HF group was 40.8%. |
Sorrentino et al[42], 2020 | Meta-analysis of 13 observational studies | 2248 | Natriuretic peptides have significant prognostic importance in predicting severity of COVID-19 | |
Yoo et al[43], 2021 | Single center, Retrospective cohort | New York | 679 | In patients without a history of HF, elevated admission NT-proBNP correlated with fewer hospital free, ICU free and ventilator free days compared to those with low NT-proBNP levels |
Alvarez-Garcia et al[44], 2020 | Single center, Retrospective | New York | 6439 | No difference identified in the level of NP and COVID-19 disease severity |
Dawson et al[45], 2020 | Meta-analysis | China | 12 studies included | |
Abdeen et al | Single center, Retrospective | New Jersey | 230 | |
Role in outcome and mortality | ||||
Gao et al[48], 2020 | Single center, Retrospective | China | 102 | Natriuretic peptides independently associated with in-hospital mortality in severe COVID-19 patients. The cut off value predicting in hospital death was 88.64 pg/mL with a 100% sensitivity and 66.7% specificity. |
Caro-Codón et al[40], 2021 | Population | Spain | 396 | Elevations in NP correlated with in-hospital mortality, even after adjusting for relevant confounders |
Calvo-Fernández A et al[49], 2021 | Single center, Retrospective | Spain | 872 | Natriuretic peptide elevation is independently related to death or mechanical ventilation in COVID-19 patients |
Selcuk et al[50], 2021 | Single center, Retrospective | Istanbul | 137 | Among patients who did not have a baseline diagnosis of HF, NPs were independent predictors of mortality. This study used a cut off threshold of 260pg/ml predicting an in-hospital mortality with 82% sensitivity and 93% specificity |
Iorio et al[51], 2022 | Multicenter, Retrospective observational | Italy | 341 | The level of NP elevation correlated with mortality. Cut off threshold used in this study is 2598 pg/L predicting a 30-d mortality with 91.7% sensitivity and an 80% specificity |
Belarte-Tornero et al[52], 2021 | Single center, Retrospective | Spain | 129 | |
Dalia et al[53], 2021 | Systematic review | India | 5967 | Patients with fulminant COVID-19 and elevated NPs had an eight-fold increased risk of acute cardiac injury and death when compared to their counterparts |
Pranata et al | Meta analysis | 967 | In patients with HF, natriuretic peptide elevation is associated with disease progression and mortality. This effect was seen even after adjustment for troponin and CKMB | |
Iorio et al[51], 2022 | Multicenter, Retrospective observational | Italy | 341 | The combined effect of cTn and NT-proBNP was studied in COVID-19 patients. Irrespective of prior HF history, increased mortality was seen in patients with both biomarker elevation. In patients with only one biomarker elevation, case fatality higher in patients with NP elevation |
Stefanini et al[55], 2020 | Single center, Retrospective | Italy | 397 |
- Citation: Muthyala A, Sasidharan S, John KJ, Lal A, Mishra AK. Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2. World J Virol 2022; 11(5): 375-390
- URL: https://www.wjgnet.com/2220-3249/full/v11/i5/375.htm
- DOI: https://dx.doi.org/10.5501/wjv.v11.i5.375